Innovative approaches for the development of antidepressant drugs: Current and future strategies
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“The direct physiological significance of antidepressant-induced neurogenesis has yet to be demonstrated, although blockade of hippocampal cell proliferation via irradiation prevents the behavioral actions of antidepressant drugs.(231) These findings have led to the neurogenenic hypothesis of antidepressant activity, w…”
BackgroundVale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Self-citationHippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932
Neurobiology of emotion perception II: implications for major psychiatric disorders
Phillips, M. L., Drevets, W. C., Rauch, S. L., & Lane, R. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00171-9 · Cited by 1,736 · cited 1×
“The framework in which one can base the comorbidity of depression and cognitive deficits can certainly be related to overlapping and reciprocal neural networks in the brain.(16,17) Nonetheless, it is still not clear if the neurodegenerative aspects play a major role in the etiology of the disease or are secondary as a…”
BackgroundBrain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378 · cited 2×
“findings in depressed patients, and can be normalized after successful antidepressant treatment.(178,179) In-”
BackgroundDunn, A. J., & Berridge, C. W. (1990) · Brain Research Reviews · doi:10.1016/0165-0173(90)90012-d · Cited by 1,352 · cited 1×
“The CRF system extends throughout the CNS and plays an important role integrating the body’s endocrine, autonomic, immune, and behavioral responses to stress.(176,177) Through neurosecretory terminals in the median eminence, CRF-synthesizing neurons of the hypothalamic paraventricular nucleus (PVN) release CRF into po…”
Background
Cited by
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100
“Despite this lack of a one-to-one correspondence between specific serotonin receptors and individual behavioral processes, various drugs targeting central serotonergic activity and serotonergic receptors are currently used clinically or are in clinical development for the treatment of nearly every neuropsychiatric dis…”
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 336
Self-citationWhat's wrong with my mouse model?
Kalueff, A. V., Wheaton, M., & Murphy, D. L. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.01.023 · Cited by 285
Xu, Y., Ku, B., Cui, L., Li, X., Barish, P. A., Foster, T. C., & Ogle, W. O. (2007) · Brain Research · doi:10.1016/j.brainres.2007.05.071 · Cited by 283
Aleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
“Subsequent drug discovery efforts focused on the rational design of compounds with similar efficacy, but improved tolerability; themost notable example is selective serotonin reuptake inhibitors (SSRIs).([7]) LEADING ARTICLE Drugs 2012; 72 (10): 1313-1333 0012-6667/12/0010-1313/$55.”
BackgroundEsmaily, H., Sahebkar, A., Iranshahi, M., Ganjali, S., Mohammadi, A., Ferns, G., & Ghayour-Mobarhan, M. (2015) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-015-2160-z · Cited by 192
Kumar, B., Kuhad, A., & Chopra, K. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2094-2 · Cited by 177
“It is characterized by a pervasive low mood, loss of interest in usual activities, diminished ability to experience pleasure (anhedonia), withdrawal of interest, feelings of worthlessness, and suicidal tendencies (Percaccio et al. 2005; SaletuZyhlarz et al. 2003; Schechter et al. 2005; Strauman et al. 2006).”
BackgroundConvergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
Liu, D., Wang, Z., Gao, Z., Xie, K., Zhang, Q., Jiang, H., & Pang, Q. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.068 · Cited by 151
“Depression is a chronic, recurring and potentially lifethreatening mood disorder that has been estimated to affect 21% of the world population [1].”
BackgroundJain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132
“Medications that act on multiple neurotransmitter systems and receptor subtypes, and that are targeted to specific aspects of the neurobiology of depression, may offer advantages in efficacy and tolerability over currently available antidepressants (Schechter et al. 2005).”
BackgroundRenoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107
“…release (e.g., 5-HT1, 5-HT2, and α-2 adrenergic receptors), multiple targets (e.g., glutamate/GABA, peptidergic systems, neurotrophic factors, hypothalamic-pituitary-adrenal axis, etc.) are likely to be involved in the mechanism of action of SSRIs (Schechter et al., 2005; Renoir et al., 2012).”
BackgroundMalberg, J. E., Platt, B., Rizzo, S. J. S., Ring, R. H., Lucki, I., Schechter, L. E., & Rosenzweig-Lipson, S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301358 · Cited by 101
Self-citationRepeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex
Tokarski, K., Bobula, B., Wabno, J., & Hess, G. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.03.007 · Cited by 65
Intravenous Ketamine “Burst” for Refractory Depression in a Patient with Advanced Cancer
Stefanczyk-Sapieha, L., Oneschuk, D., & Demas, M. (2008) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.9828 · Cited by 61
Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission
Hoshaw, B. A., Hill, T. I., Crowley, J. J., Malberg, J. E., Khawaja, X., Rosenzweig-Lipson, S., Schechter, L. E., & Lucki, I. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.023 · Cited by 60
Self-citationTargeting TrkB neurotrophin receptor to treat depression
Rantamäki, T., & Castrén, E. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.705 · Cited by 40
Metadata
- Authors
- Schechter, L. E., Ring, R. H., Beyer, C. E., Hughes, Z. A., Khawaja, X., Malberg, J. E., & Rosenzweig-Lipson, S.
- Venue
- NeuroRX
- Published
- 2005-10
- Volume
- 2
- Issue
- 4
- Pages
- 590-611
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2028306465
- Cited by
- 228
- References
- 50
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.